UK markets closed

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.6950-0.1750 (-6.10%)
As of 01:18PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 101.45M
Enterprise value 35.05M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.64
Price/book (mrq)0.47
Enterprise value/revenue 1.11
Enterprise value/EBITDA -0.26

Trading information

Stock price history

Beta (5Y monthly) 2.18
52-week change 3-86.89%
S&P500 52-week change 311.79%
52-week high 330.1000
52-week low 32.6800
50-day moving average 33.7580
200-day moving average 39.2035

Share statistics

Avg vol (3-month) 3943.4k
Avg vol (10-day) 3392.31k
Shares outstanding 535.35M
Implied shares outstanding 635.35M
Float 835.02M
% held by insiders 1N/A
% held by institutions 1N/A
Shares short (14 Sept 2023) 45.1M
Short ratio (14 Sept 2023) 45.55
Short % of float (14 Sept 2023) 414.49%
Short % of shares outstanding (14 Sept 2023) 414.42%
Shares short (prior month 14 Aug 2023) 44.14M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 306 Aug 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 0.00%
Operating margin (ttm)-458.99%

Management effectiveness

Return on assets (ttm)-30.49%
Return on equity (ttm)-58.67%

Income statement

Revenue (ttm)31.51M
Revenue per share (ttm)1.05
Quarterly revenue growth (yoy)29.90%
Gross profit (ttm)5.95M
EBITDA -133.02M
Net income avi to common (ttm)-146.52M
Diluted EPS (ttm)-7.4500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)77.06M
Total cash per share (mrq)2.18
Total debt (mrq)10.66M
Total debt/equity (mrq)4.97%
Current ratio (mrq)3.66
Book value per share (mrq)6.46

Cash flow statement

Operating cash flow (ttm)-133.1M
Levered free cash flow (ttm)-73.33M